Other headlinesGMI builds clinical war ches
Toshiba boosts Infinix image quality
Toshiba America Medical Systems unveiled Sept 21 a low-contrast capability for Infinix-i systems that feature mid- and large-size flat panel detectors. The new capability was a feature of its exhibit at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The Low-Contrast Imaging (LCI) technology enables better visualization of soft tissue in the angio suite, according to the company, delivering CT-like images of the liver, brain, and cerebral ventricles. LCI may be used to improve diagnosis, as well as to confirm appropriate endpoints during interventional procedures, such as aortic stent-grafting, the company said. The Infinix-i line features a five-axis C-arm that covers patients head-to-toe and fingertip-to-fingertip.
GMI builds clinical war chest
Gamma Medica-Ideas has raised $24 million to support efforts to grow its presence in the clinical marketplace with digital SPECT, PET, and CT products. Psilos Group, a healthcare venture capital firm, and Capital Resource Partners, a provider of hybrid growth financing, contributed $14 million in equity capital. Capital Resource Partners also provided $5 million in mezzanine debt. The technology lending group at Bridge Bank rounded out the financing with a $5 million revolving line of credit. Historically, GMI has served the pre-clinical imaging market, where the need for increased productivity is driving demand for medical research and drug discovery applications. Its small animal imaging products are distributed in Japan by SII NanoTechnology and elsewhere by GE Healthcare. With this financing, GMI plans to leverage its digital imaging technology platform into clinical imaging markets, where the company will promote its products as the means to improved diagnosis at lower costs. GMI’s initial product, LumaGEM, is focused on improving the diagnosis of cancers in women with dense breast tissue.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.